Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug

Blockhead12-17

Teva stock catapulted Tuesday and was on deck to open at a five-year high after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study. ↑ X How To Buy ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492969980?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2022/07/Stock-tevapharmaceuticals-01-adobe-150x150.jpg","is_english":true,"pubTime":"2024-12-17 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492969980","market":"sg","top_or_hot":-1,"title":"Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug","media":"Blockhead","content":"<div>\n<p>Teva stock catapulted Tuesday and was on deck to open at a five-year high after its inflammatory bowel disease treatment showed \"best-in-class potential\" in a Phase 2 study.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy ...</p>\n\n<a href=\"https://www.investors.com/news/technology/teva-stock-sanofi-stock-inflammatory-bowel-disease-drug/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/teva-stock-sanofi-stock-inflammatory-bowel-disease-drug/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teva stock catapulted Tuesday and was on deck to open at a five-year high after its inflammatory bowel disease treatment showed \"best-in-class potential\" in a Phase 2 study.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy ...</p>\n\n<a href=\"https://www.investors.com/news/technology/teva-stock-sanofi-stock-inflammatory-bowel-disease-drug/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4596","symbol_name":"哈里斯概念","start_time":0,"source_url":"https://www.investors.com/news/technology/teva-stock-sanofi-stock-inflammatory-bowel-disease-drug/","article_id":"2492969980","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2022/07/Stock-tevapharmaceuticals-01-adobe-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492969980","pubTimestamp":1734445054,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed \"best-in-class potential\" in a Phase 2 study.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4596":"哈里斯概念","BK4007":"制药","BK4566":"资本集团","SNY":"赛诺菲安万特","TEVA":"梯瓦制药","BK4584":"避孕概念","BK4557":"大麻股","SNYNF":"Sanofi","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4559":"巴菲特持仓","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"梯瓦(Teva)凭借与赛诺菲(Sanofi)并列的药物获胜后，股价飙升20%，接近五年高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"SNYNF":1,"TEVA":1},"content_text":"Teva stock catapulted Tuesday and was on deck to open at a five-year high after its inflammatory bowel disease treatment showed \"best-in-class potential\" in a Phase 2 study.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: 4 Factors For Finding Quality Trade Ideas\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: 4 Factors For Finding Quality Trade Ideas\n\n\n\n\nTeva Pharmaceutical (TEVA) tested its drug, dubbed duvakitug, in patients with ulcerative colitis and Crohn's disease. In the former group, 36.2% of patients who received a low-dose of the drug and 47.8% of the high-dose group reached clinical remission vs. just 20.5% of the placebo group.\nIn the Crohn's disease group, 26.1% and 47.8% of the low-dose and high-dose recipients, respectively, showed endoscopic responses vs. just 13% of the placebo group. An endoscopic response means signs of the disease disappeared under an endoscopy.\nTeva stock soared more than 20% to 19.96 in premarket trades. Shares look likely to open at their highest point since February 2019. Shares of Sanofi (SNY), Teva's partner, jumped 4.4% to 47.89.\nMore to follow.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nPfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook\nBattle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?\nHow To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks\nGet Timely Buy & Sell Alerts With IBD Leaderboard\nLooking For The Next Big Stock Market Winners? Start With These 3 Steps","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492969980"}